How an Ebola vaccine candidate activates our immune system
In 2016, a clinical phase I trial on a potential vaccine against the dreaded Ebola virus was successfully completed. In a further trial, DZIF scientists have now shown in detail how our immune systems react to the tested vaccine "rVSV-ZEBOV" for the first time.
"Good to see both sides"
Oumou Maiga-Ascofaré is currently working as a research fellow at the Bernhard Nocht Institute for Tropical Medicine in Hamburg and at the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) in Kumasi, Ghana. We asked her about her work in DZIF and her life among different cultures.
A list of pathogens sets priorities for antibiotic research
The WHO has published a list of 12 bacteria groups which are to be given priority for future new antibiotic research and development. DZIF scientists at the University of Tübingen were substantially involved in developing this priority list.
New malaria vaccine effective in clinical trial
Researchers of the University of Tübingen and DZIF in collaboration with the biotech company Sanaria Inc. have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of vaccine.
02 May 2017 - PRESS RELEASE
Researchers at the ImmunoSensation cluster of excellence at the University of Bonn have managed to do what many scientists dream of: together with researchers from the USA, they have patented new molecules that allow the immune system to be directed against tumor cells. The license has already given the University of Bonn a first payment – and the scientists also gained a share. [ more ]
18 April 2017 - PRESS RELEASE
13 April 2017 - PRESS RELEASE
DZIF e. V. – Inhoffenstraße 7, 38124 Braunschweig, Germany
PHONE +49 531-6181 1152 EMAIL email@example.com